3. IVIG shortage recommendations In May 2018 circulated the English-language version of a Quebec document addressing utilization of IVIG / SCIG during a shortage Breaks down into amber and red levels Identifies conditions that have priority Includes other steps (e.g. decreasing trough levels for patients with primary immunodeficiency)

Feedback Guidelines don’t really line up with our local indications Do we need national agreement on indications before creating a national shortage approach? Remove pediatric NAIT from amber Missing abbreviations

Food For Thought . . . . Do we need shortage guidelines for IVIG / SCIG? If yes, the NAC the right group to produce them? Do one exist that can be endorsed as-is? Do we want to ask CBS PTBLC to add this to our workplan?